Ex-Sanofi chief Olivi­er Brandi­court, cur­rent Black­stone ad­vi­sor, jumps on Al­ny­lam board

For­mer Sanofi chief Olivi­er Brandi­court, who de­part­ed his post with an un­ex­pect­ed ear­ly re­tire­ment last year, has made his move — as most C-suite ex­ec­u­tives in­evitably do — to be­come a di­rec­tor on the board of a bio­phar­ma com­pa­ny.

RNAi play­er Al­ny­lam is Brandi­court’s des­ti­na­tion. Mean­while, the Cam­bridge, Mass­a­chu­setts-based drug­mak­er — which pi­o­neered the first ap­proval in the field — al­so dis­closed the re­tire­ment of Al­ny­lam co-founder Dr. Paul Schim­mel from its board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER